The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

Post-translational acetylation of lysine residues has emerged as a key regulatory
mechanism in all eukaryotic organisms. Originally discovered in 1963 as a unique …

The antineoplastic, prodifferentiative effects of bromodomain and extra-terminal (BET)
bromodomain (BRD) inhibitors were initially discovered in NUT midline carcinoma (NMC) …

Histone lysine acetylation is critical in regulating transcription. Dysregulation of this process
results in aberrant gene expression in various diseases, including cancer. The …

In the past few years, it has become clear that mutations in epigenetic regulatory genes are
common in human cancers. Therapeutic strategies are now being developed to target …

Background Bromodomain and extra-terminal domain proteins are promising epigenetic
anticancer drug targets. This first-in-human study evaluated the safety, recommended phase …

Background NUT midline carcinoma, renamed NUT carcinoma (NC), is an aggressive
squamous cancer defined by rearrangement of the NUTM1 gene. Although a subset of …

The bromodomain (BRD) and extraterminal (BET) proteins including BRD2, BRD3 and
BRD4 have been identified as key targets for leukemia maintenance. A novel oral inhibitor of …

Clinical development of bromodomain and extra‐terminal (BET) protein inhibitors differs
from the traditional course of drug development. These drugs are simultaneously being …

NUT carcinoma (NC) is a rare, aggressive subtype of squamous cell carcinoma defined by
rearrangement of the NUTM1 (aka NUT) gene. NC is driven by NUT‐fusion oncoproteins …